UniQure NV - Company Profile
Powered by 
All the data and insights you need on UniQure NV in one report.
$295
- Save hours of research time and resources with
our up-to-date UniQure NV Strategy Report
- Understand UniQure NV position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
UniQure NV Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of UniQure NV Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 29 Apr 2020 | Lorem |
| UniQure’s etranacogene dezaparvovec in haemophilia B has experts positive on Phase III prospects despite division over neutralizing antibodies | 02 Dec 2019 | Ayisha Sharma |
| Parkinson’s gene therapy previously developed by UniQure to enter a Phase II this summer under a new private-public entity, lead researcher says | 19 Mar 2019 | Shuan Sim |
| UniQure’s Parkinson’s gene therapy has investigators discussing protocol amendments to revive development; data from original Phase I submitted to journal, investigator says | 27 Feb 2019 | Shuan Sim |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer